Denali Therapeutics Secures $200M Royalty Funding Following U.S. FDA Accelerated Approval Of Tividenofusp Alfa

Item 7.01    Regulation FD Disclosure.

Royalty Agreement Closing and Funding

On March 27, 2026, the Company received $200.0 million in gross proceeds in connection with the closing of the transactions under the Royalty Agreement. The closing followed the U.S. Food and Drug and Administration's accelerated approval of tividenofusp alfa on March 24, 2026.